Alzheimer’s Disease-Like Neurodegeneration in Porphyromonas gingivalis Infected Neurons with Persistent Expression of Active Gingipains. Journal of Alzheimer’s Disease 2020.
Treatment of Porphyromonas gulae infection and downstream pathology in the aged dog by lysine-gingipain inhibitor COR388. Pharmacology Research and Perspectives, 2020.
Porphyromonas gingivalis in Alzheimer’s disease brains: Evidence for disease causation and treatment with small-molecule inhibitors. Science Advances, 2019.
PRESENTATION: ADDITIONAL DATA FROM THE PHASE 2/3 GAIN TRIAL OF COR388 (ATUZAGINSTAT) FOR THE TREATMENT OF MILD TO MODERATE ALZHEIMER’S DISEASE. AD/PD 2022.
PRESENTATION: Use of Novel Biomarkers of P. Gingivalis Infection & Neuroinflammation in the GAIN Trial. Biomarkers for Alzheimer’s Disease Summit 2021.
PRESENTATION: AAIC 2021 Cortexyme Symposium: Getting to the Root Cause of Alzheimer’s Disease: An Innovative, Upstream Approach for Disease Modification
An update and baseline data from the Phase 2/3 GAIN trial of COR388 (atuzaginstat) a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s Disease. AAIC 2021.
Presentation: An update and baseline data from the Phase 2/3 GAIN trial of COR388 (atuzaginstat) a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s Disease. ASCP 2021.
Poster: An update and baseline data from the Phase 2/3 GAIN trial of COR388 (atuzaginstat) a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s Disease. ASCP 2021.
Ultrastructural localization of Porphyromonas gingivalis RgpB virulence factor in the middle temporal gyrus (MTG) of the Alzheimer’s disease human brain. AAT-AD/PD 2021.
PD-L1 is induced by the periodontal pathogen Porphyromonas gingivalis and can be blocked by small molecule gingipain inhibitors, including atuzaginstat. SITC 2020.
Comprehensive Alzheimer’s pathology is induced by P. gingivalis infection: COR388 and other gingipain inhibitors protect against synaptic loss. AAIC 2020.
Initiation of the Phase 2/3 GAIN trial of COR388, a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s Disease based on Phase 1 a/b safety, PK, biomarker, and efficacy data. AAIC 2019.
Chronic oral application of a periodontal pathogen results in brain inflammation, neurodegeneration and amyloid beta production in wild type mice. PLoS One 2018.
Tran et al. Effects of Porphyromonas gingivalis and Its Underlying Mechanisms on Alzheimer-Like Tau Hyperphosphorylation in Sprague-Dawley Rats. Journal of Molecular Neuroscience 2020.
Periodontitis Deteriorates Cognitive Function and Impairs Neurons and Glia in a Mouse Model of Alzheimer’s Disease. Journal of Alzheimer’s Disease 2021.
Determining the Presence of Periodontopathic Virulence Factors in Short-Term Postmortem Alzheimer’s Disease Brain Tissue. Journal of Alzheimer’s Disease 2013.
The lysine-specific gingipain of Porphyromonas gingivalis: Importance to pathogenicity and potential strategies for inhibition. Advances in Experimental Medicine and Biology 2011.
Braak et al. Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. Journal of Neural Transmission 2003
Oral P. gingivalis impairs gut permeability and mediates immune responses associated with neurodegeneration in LRRK2 R1441G mice. Journal of Neuroinflammation 2020.
Periodontal inflammatory disease is associated with the risk of Parkinson’s disease: a population-based retrospective matched-cohort study. PeerJ. 2017.
Dental Scaling Decreases the Risk of Parkinson’s Disease: A Nationwide Population-Based Nested Case-Control Study. International Journal of Environmental Research and Public Health. 2018.
Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects. Journal of Neural Transmission. 2019.
Presence of Porphyromonas gingivalis in esophagus and its association with the clinicopathological characteristics and survival in patients with esophageal cancer. Infectious Agents and Cancer. 2016
